Switch theme
Sign up to access all valuation multiples
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
1960
561
LTM Revenue $203M
LTM EBITDA $1.0M
$567M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TTY Biopharm has a last 12-month revenue (LTM) of $203M and a last 12-month EBITDA of $1.0M.
In the most recent fiscal year, TTY Biopharm achieved revenue of $197M and an EBITDA of $70.9M.
TTY Biopharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TTY Biopharm valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $203M | XXX | $197M | XXX | XXX | XXX |
| Gross Profit | $118M | XXX | $114M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $1.0M | XXX | $70.9M | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | 36% | XXX | XXX | XXX |
| EBIT | $48.7M | XXX | $46.5M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $48.0M | XXX | $48.4M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TTY Biopharm's stock price is TWD 75 (or $3).
TTY Biopharm has current market cap of TWD 18.7B (or $624M), and EV of TWD 17.0B (or $567M).
See TTY Biopharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $567M | $624M | XXX | XXX | XXX | XXX | $0.18 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TTY Biopharm has market cap of $624M and EV of $567M.
TTY Biopharm's trades at 2.9x EV/Revenue multiple, and 8.0x EV/EBITDA.
Equity research analysts estimate TTY Biopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TTY Biopharm has a P/E ratio of 13.0x.
See valuation multiples for TTY Biopharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $624M | XXX | $624M | XXX | XXX | XXX |
| EV (current) | $567M | XXX | $567M | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 551.4x | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBIT | 11.6x | XXX | 12.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.0x | XXX | 12.9x | XXX | XXX | XXX |
| EV/FCF | 13.4x | XXX | 14.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTTY Biopharm's last 12 month revenue growth is 4%
TTY Biopharm's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
TTY Biopharm's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TTY Biopharm's rule of X is 11% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TTY Biopharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | -87% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TTY Biopharm acquired XXX companies to date.
Last acquisition by TTY Biopharm was XXXXXXXX, XXXXX XXXXX XXXXXX . TTY Biopharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TTY Biopharm founded? | TTY Biopharm was founded in 1960. |
| Where is TTY Biopharm headquartered? | TTY Biopharm is headquartered in Taiwan. |
| How many employees does TTY Biopharm have? | As of today, TTY Biopharm has 561 employees. |
| Is TTY Biopharm publicy listed? | Yes, TTY Biopharm is a public company listed on ROCO. |
| What is the stock symbol of TTY Biopharm? | TTY Biopharm trades under 4105 ticker. |
| When did TTY Biopharm go public? | TTY Biopharm went public in 2001. |
| Who are competitors of TTY Biopharm? | Similar companies to TTY Biopharm include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TTY Biopharm? | TTY Biopharm's current market cap is $624M |
| What is the current revenue of TTY Biopharm? | TTY Biopharm's last 12 months revenue is $203M. |
| What is the current revenue growth of TTY Biopharm? | TTY Biopharm revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of TTY Biopharm? | Current revenue multiple of TTY Biopharm is 2.8x. |
| Is TTY Biopharm profitable? | Yes, TTY Biopharm is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TTY Biopharm? | TTY Biopharm's last 12 months EBITDA is $1.0M. |
| What is TTY Biopharm's EBITDA margin? | TTY Biopharm's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of TTY Biopharm? | Current EBITDA multiple of TTY Biopharm is 551.4x. |
| What is the current FCF of TTY Biopharm? | TTY Biopharm's last 12 months FCF is $42.4M. |
| What is TTY Biopharm's FCF margin? | TTY Biopharm's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of TTY Biopharm? | Current FCF multiple of TTY Biopharm is 13.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
